News | October 20, 2008

FDA Gives 510(K) Clearance to InnerCool's RapidBlue Endovascular System

October 21, 2008 - Cardium Therapeutics and its operating unit InnerCool Therapies Inc. said the FDA gave 510(k) clearance to market the RapidBlue System, an endovascular temperature modulation device.

InnerCool’s RapidBlue System is a thermal regulating system designed to manage and control patient body temperature. This new system automatically cools or warms patients, as necessary, to quickly and controllably achieve and then maintain a desired body temperature. RapidBlue provides rapid or gradual temperature control for all patient sizes. Its closed loop catheter-based system modulates whole body temperature, without fluid introduction or exchange, by circulating cool or warm saline within the interior of the catheter. RapidBlue is reportedly powerful enough to quickly cool awake patients and may eliminate the need to use paralytic agents. The system reportedly combines a high-performance programmable console with an enhanced user-friendly interface.

For more information: www.cardiumthx.com

Related Content

therapeutic hypothermia, children, cardiac arrest, treatment, temperature
Feature | May 04, 2015
A large-scale, multicenter study has shown that therapeutic hypothermia does not improve survival rates or reduce brain...
News | December 11, 2014
Researchers at Okayama University in collaboration with several medical centers in Japan have demonstrated the safety...
Feature | September 19, 2014
September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-...
Technology | July 10, 2014
July 10, 2014 — Life Recovery Systems announced the U.S. Food and Drug Administration (FDA) has approved two...
therapeutic hypothermia, Philips InnerCool

The Philips InnerCool RTx system was used in the CHILL-MI study for use in STEMI patients.

Feature | February 03, 2014 | Dave Fornell
Use of therapeutic hypothermia is used to prevent neurological damage in patients who suffer sudden cardiac arrest (SCA...
BeneChill RhinoChill Therapeutic Hypothermia Cath Lab Intranasal Cooling System
News | January 22, 2014
BeneChill Inc. received the 2014 Frost & Sullivan Award for Technology Innovation Leadership for its RhinoChill...
rhinochill, RhinoChill, benechill, BeneChill

RhinoChill IntraNasal Cooling System

News | December 03, 2013
With the benefits of conventional strategies for therapeutic hypothermia following cardiac arrest being called in to ...
therapeutic hypothermia temperature management cath lab clinical trial study
Feature | November 01, 2013
clinical trial shows that rapidly cooling...
News | October 01, 2013
The Cardiovascular Research Foundation (CRF) announced the late breaking trials and first report investigations that...
News | August 06, 2013
Vanderbilt Heart and Vascular Institute is participating in the VELOCITY study, a randomized controlled clinical study...
Overlay Init